Isothiocyanates as specific antagonists of human SXR

描述（由申请方提供）：药物不良相互作用（ADI）是美国的一个主要公共卫生问题。ADI和治疗效果失败的主要原因是遗传变异性和/或环境诱导的（包括饮食）肝脏和肠道药物处置的变化。细胞色素P450 3A 4（CYP 3A 4）负责许多外源性物质的肝脏和肠道代谢，包括药物化合物，一些致癌物质和几种重要的内源性类固醇。CYP 3A 4的组成型和诱导型表达受多种不同的转录因子/途径调节。CYP 3A 4活性的最重要决定因素是激素核受体，类固醇和异生物质受体（SXR;也称为孕烷X受体，PXR）。许多药物和非药物化学品通过作为SXR配体诱导CYP 3A 4活性，并可引起显著的药物间不良相互作用并改变疗效。在最初调查膳食植物化学物质萝卜硫素（SFN;在花椰菜中发现的异硫氰酸酯）的化学预防作用的研究中，我们发现SFN导致人类肝细胞中CYP 3A 4的显著下调。然后，我们在人源性肠细胞（LS-180）中验证了这种作用，然后证明SFN在低微摩尔浓度下作为配体与SXR结合的有效拮抗剂。其他研究表明，这是种属（人类）特异性效应，与啮齿动物和人类之间SXR配体的已知差异一致。本研究拟：1）进一步阐明SFN阻断SXR功能的分子机制; 2）评价SFN的结构类似物以鉴定更有效和/或特异的SXR拮抗剂; 3）利用“人源化”SXR小鼠和其他体内方法建立人类应答的动物模型，和4）进行一系列人类喂养研究以确定花椰菜芽中的SFN是否降低人CYP 3A 4的基础表达和/或干扰利福平介导的CYP 3A 4诱导，通过咪达唑仑清除率测量。如果基础喂养研究确定了对CYP 3A 4的影响，则建议进行额外的喂养研究，以检查其他SFN类似物，并进一步表征影响的剂量和时间过程。这些结果可能会导致重要的新的治疗和饮食方法，可以减少药物不良反应的发展。它们还可以帮助解释几十年来人们一直注意到的CYP 3A 4的个体间变异性。最后，他们可以帮助进一步阐明萝卜硫素的风险和益处，萝卜硫素是一种潜在的膳食植物化学物质，已被提议作为一种安全的“营养”化合物，以降低癌症风险。

DESCRIPTION (provided by applicant): Adverse drug interactions (ADI), are a major public health problem in the US. A major contributor to both ADI and failure of therapeutic efficacy is genetic variability and/or environmentally-induced (incl. diet) changes in hepatic and intestinal drug disposition. Cytochrome P450 3A4 (CYP3A4) is responsible for the hepatic and intestinal metabolism of numerous xenobiotics, including pharmaceutical compounds, some carcinogens, and several important endogenous steroids. Constitutive and inducible expression of CYP3A4 is regulated by a variety of different transcription factors/pathways. Among the most important determinants of CYP3A4 activity is the hormone nuclear receptor, Steroid and Xenobiotic Receptor (SXR; also known as the Pregnane X-receptor, PXR). Numerous drugs and non-drug chemicals induce CYP3A4 activity by acting as SXR ligands, and can cause significant adverse drug-drug interactions and alter therapeutic efficacy. In studies initially investigating the chemopreventive actions of the dietary phytochemical, sulforaphane (SFN; an isothiocyanate found in broccoli), we found that SFN causes remarkable 'down-regulation of CYP3A4 in human hepatocytes. We then verified this effect in human-derived intestinal cells (LS-180), and then demonstrated that SFN acts as an effective antagonist of ligand binding to SXR at low micromolar concentrations. Additional studies demonstrated that this is a species (human)-specific effect, consistent with known differences in SXR ligands between rodents and humans. In this grant we propose to: 1) further elucidate the molecular mechanisms by which SFN blocks SXR function; 2) evaluate structural analogs of SFN to identify more potent and/or specific SXR antagonists; 3) utilize 'humanized' SXR mice and other in vivo approaches to establish an animal model for human response, and 4) conduct a series of human feeding studies to determine if SFN in broccoli sprouts lowers basal expression of human CYP3A4 and/or interferes with rifampicin-mediated induction of CYP3A4, measured by midazolam clearance. If the basic feeding study identifies an effect on CYP3A4, additional feeding studies are proposed to examine other SFN analogs and further characterize the dose and time course of effects. These results may lead to the development of important new therapeutic and dietary approaches that could reduce adverse drug responses. They could also help explain the large inter-individual variability in CYP3A4 that has been noted for decades. Finally, they could help to further elucidate the risks and benefits of sulforaphane, a potential dietary phytochemical that has been proposed as a safe 'nutraceutical' compound to reduce cancer risk.